Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 8/20 | 0.38 |
| ▸ | FGFR4 | P22455 | 8/20 | 0.38 |
| ▸ | PI4KA | P42356 | 4/20 | 0.38 |
| ▸ | PI4K2B | Q8TCG2 | 4/20 | 0.38 |
| ▸ | PI4K2A | Q9BTU6 | 4/20 | 0.38 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10910542 | 0.79 | FDPS (0.47) | FDPSP2RX7HDAC6FGFR1FGFR4 | |
| SCHEMBL667204 | 0.77 | ADORA2A (0.62) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL26348841 | 0.75 | FDPS (0.44) | FDPSP2RX7HDAC6FGFR1FGFR4 | |
| SCHEMBL16949893 | 0.75 | ADORA2A (0.37) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL28174152 | 0.75 | ADORA2A (0.37) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL15829723 | 0.75 | ADORA2A (0.37) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL30572667 | 0.75 | ADORA1 (0.60) | FDPSP2RX7HDAC6FGFR1FGFR4 | |
| SCHEMBL130453 | 0.75 | ADORA1 (0.60) | FDPSP2RX7HDAC6FGFR1FGFR4 | |
| SCHEMBL16949944 | 0.75 | ADORA2A (0.37) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL27960571 | 0.75 | FDPS (0.44) | FDPSP2RX7HDAC6FGFR1FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102942582-A | Preparation method of entecavir key intermediate | KAMP PHARMACEUTICALS CO LTD | 2013-02-27 | — | — | CN | claimed |
| CN-117795096-A | Methods, compositions and kits for preparing sequencing libraries | 吉复生物科技有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-115884977-A | Stereoselective preparation of selected purine phosphoramidates | 阿堤亚制药公司 | 2023-03-31 | — | — | CN | disclosed |
| US-20220152078-A1 | 2'3'-CYCLIC DINUCLEOTIDES AND PRODRUGS THEREOF | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2022-05-19 | — | — | US | disclosed |
| CN-113292564-B | Synthetic method of 2-amino-6-chloropurine | 上海凌凯医药科技有限公司 | 2022-04-19 | — | — | CN | disclosed |
| US-10253360-B2 | BNA clamp method | BNA INC. (JP) | 2019-04-09 | — | — | US | disclosed |
| WO-2019067740-A1 | FUSION PROTEINS HAVING A TOXIN AND CANCER MARKER, NANOPARTICLES, AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2019-04-04 | — | — | WO | disclosed |
| CN-109420480-A | A kind of separation method of C 4 olefin mixture | 浙江大学 | 2019-03-05 | — | — | CN | disclosed |
| CN-109312338-A | CRISPR/CAS related methods and compositions for treating herpes simplex virus | 爱迪塔斯医药公司 | 2019-02-05 | — | — | CN | disclosed |
| EP-2902499-B1 | BNA CLAMP METHOD | BNA INC (JP) | 2018-09-12 | — | — | EP | disclosed |
| EP-1534708-B1 | PURINE DERIVATIVES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | CYCLACEL LTD (GB) | 2006-04-26 | — | — | EP | disclosed |
| EP-0773220-B1 | 2-Amino-6-chloropurine and method for preparing the same | SUMIKA FINE CHEMICALS CO LTD (JP) | 2002-02-13 | — | — | EP | disclosed |
| US-6187921-B1 | 2-AMINO-6-CHLOROPURINE HAVING DOUBLE CONE-LIKE CRYSTAL FORM CONSTRUCTED BY COMBINING TWO PYRAMIDS WITH EACH OTHER AT THEIR BOTTOMS AND HAVING SPECIFIED AVERAGE PARTICLE DIAMETER | SUMIKA FINE CHEMICALS CO., LTD. (JP) | 2001-02-13 | — | — | US | disclosed |
| EP-1017394-A1 | CYCLIN DEPENDENT KINASE INHIBITING PURINE DERIVATIVES | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2000-07-12 | — | — | EP | disclosed |
| WO-1999002162-A1 | CYCLIN DEPENDENT KINASE INHIBITING PURINE DERIVATIVES | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1999-01-21 | — | — | WO | disclosed |
| US-5789590-A | Double cone-like crystal form of 2-amino-6-chloropurine and preparation | SUMIKA FINE CHEMICALS CO., LTD. (JP) | 1998-08-04 | — | — | US | disclosed |
| EP-0773220-A1 | 2-Amino-6-chloropurine and method for preparing the same | SUMIKA FINE CHEMICALS Co., Ltd. (JP) | 1997-05-14 | — | — | EP | disclosed |
| EP-0719273-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1996-07-03 | — | — | EP | disclosed |
| WO-1995007920-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1995-03-23 | — | — | WO | disclosed |
| US-5126347-A | Autoimmune deficiency syndrome | HOFFMANN-LA ROCHE INC. (US) | 1992-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10253360-B2 | BNA clamp method | SLC28A1, SLC28A2, NAAA | FDPS 4672/4885P2RX7 2042/4885HDAC6 4502/4885 |
| US-20220152078-A1 | 2'3'-CYCLIC DINUCLEOTIDES AND PRODRUGS THEREOF | STING1, CGAS, NT5C2 | FDPS 609/4885P2RX7 58/4885HDAC6 2890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.